FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3094082904> ?p ?o ?g. }

• W3094082904 endingPage "1557" @default.
• W3094082904 startingPage "1554" @default.
• W3094082904 abstract "Psoriasis-related pruritus (PRP) in patients under systemic treatment is challenging. The risk to switch anti-psoriatic drugs and to lose response to previous therapy is high, thus dermatologists prefer to add an anti-pruritic agent.To evaluate the effect of anti-histamines and aprepitant in treating PPR of psoriatic patients undergoing systemic anti-psoriatic therapies.A pilot observational open-label study was performed on responsive psoriatic patients with PPR under treatment. Initial therapy included oral rupatadine (10 mg/day for 30 days). In case of the Epworth Sleepiness Scale (ESS) was above 14, patients were switched to aprepitant (80 mg/day for 7 days), otherwise, rupatadine dosage was increased (20 mg/day for 7 days). Clinical evaluation was performed at the baseline (T0) and after 7 days (T7).We enrolled 40 patients with PPR, 20 in each group. Age, gender, Psoriatic arthritis (PsA) and the itch - VAS, were matched. At T7, aprepitant displayed higher improvements than rupatadine (itch - VAS = 4 [3-5] vs 8.5 [8-9], p < .01, DLQI = 14 [13-16] vs. 18 [16-21], p < .01 and ESS = 5 [4-7] vs 15 [14-16], p < .01). Doubling the rupatadine dosage from 10 mg to 20 mg/day only slightly improve itch (itch - VAS = 9 [8-10] vs 9 [8-9], p = .03), conversely no modifications in the quality of life (DLQI = 18 [17-20] vs 18 [17-21], p = .73) and increased sleepiness (ESS = 10 [9-11] vs 15 [14-16], p < .01).Aprepitant may be a valid alternative in PPR patients with ESS >14 under antihistamines." @default.
• W3094082904 created "2020-10-29" @default.
• W3094082904 creator A5009117393 @default.
• W3094082904 creator A5010850499 @default.
• W3094082904 creator A5022039652 @default.
• W3094082904 creator A5022644884 @default.
• W3094082904 creator A5028135237 @default.
• W3094082904 creator A5039272149 @default.
• W3094082904 creator A5048856143 @default.
• W3094082904 creator A5051244768 @default.
• W3094082904 creator A5053560080 @default.
• W3094082904 creator A5070588042 @default.
• W3094082904 creator A5089264393 @default.
• W3094082904 date "2020-10-28" @default.
• W3094082904 modified "2023-10-09" @default.
• W3094082904 title "Antihistamines-refractory chronic pruritus in psoriatic patients undergoing biologics: aprepitant vs antihistamine double dosage, a real-world data" @default.
• W3094082904 cites W1822672492 @default.
• W3094082904 cites W1969328421 @default.
• W3094082904 cites W2004372679 @default.
• W3094082904 cites W2008022647 @default.
• W3094082904 cites W2029173044 @default.
• W3094082904 cites W2059084572 @default.
• W3094082904 cites W2062640533 @default.
• W3094082904 cites W2090919416 @default.
• W3094082904 cites W2093066805 @default.
• W3094082904 cites W2160630664 @default.
• W3094082904 cites W2511178820 @default.
• W3094082904 cites W2751988648 @default.
• W3094082904 cites W2911723779 @default.
• W3094082904 cites W2922251056 @default.
• W3094082904 cites W2952185939 @default.
• W3094082904 cites W2987277440 @default.
• W3094082904 doi "https://doi.org/10.1080/09546634.2020.1840502" @default.
• W3094082904 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33084462" @default.
• W3094082904 hasPublicationYear "2020" @default.
• W3094082904 type Work @default.
• W3094082904 sameAs 3094082904 @default.
• W3094082904 citedByCount "9" @default.
• W3094082904 countsByYear W30940829042021 @default.
• W3094082904 countsByYear W30940829042022 @default.
• W3094082904 countsByYear W30940829042023 @default.
• W3094082904 crossrefType "journal-article" @default.
• W3094082904 hasAuthorship W3094082904A5009117393 @default.
• W3094082904 hasAuthorship W3094082904A5010850499 @default.
• W3094082904 hasAuthorship W3094082904A5022039652 @default.
• W3094082904 hasAuthorship W3094082904A5022644884 @default.
• W3094082904 hasAuthorship W3094082904A5028135237 @default.
• W3094082904 hasAuthorship W3094082904A5039272149 @default.
• W3094082904 hasAuthorship W3094082904A5048856143 @default.
• W3094082904 hasAuthorship W3094082904A5051244768 @default.
• W3094082904 hasAuthorship W3094082904A5053560080 @default.
• W3094082904 hasAuthorship W3094082904A5070588042 @default.
• W3094082904 hasAuthorship W3094082904A5089264393 @default.
• W3094082904 hasConcept C121332964 @default.
• W3094082904 hasConcept C126322002 @default.
• W3094082904 hasConcept C142424586 @default.
• W3094082904 hasConcept C16005928 @default.
• W3094082904 hasConcept C2776260265 @default.
• W3094082904 hasConcept C2776694085 @default.
• W3094082904 hasConcept C2776880894 @default.
• W3094082904 hasConcept C2780564577 @default.
• W3094082904 hasConcept C2780574406 @default.
• W3094082904 hasConcept C2780884295 @default.
• W3094082904 hasConcept C2781427535 @default.
• W3094082904 hasConcept C42219234 @default.
• W3094082904 hasConcept C71924100 @default.
• W3094082904 hasConcept C87355193 @default.
• W3094082904 hasConcept C90924648 @default.
• W3094082904 hasConcept C98274493 @default.
• W3094082904 hasConceptScore W3094082904C121332964 @default.
• W3094082904 hasConceptScore W3094082904C126322002 @default.
• W3094082904 hasConceptScore W3094082904C142424586 @default.
• W3094082904 hasConceptScore W3094082904C16005928 @default.
• W3094082904 hasConceptScore W3094082904C2776260265 @default.
• W3094082904 hasConceptScore W3094082904C2776694085 @default.
• W3094082904 hasConceptScore W3094082904C2776880894 @default.
• W3094082904 hasConceptScore W3094082904C2780564577 @default.
• W3094082904 hasConceptScore W3094082904C2780574406 @default.
• W3094082904 hasConceptScore W3094082904C2780884295 @default.
• W3094082904 hasConceptScore W3094082904C2781427535 @default.
• W3094082904 hasConceptScore W3094082904C42219234 @default.
• W3094082904 hasConceptScore W3094082904C71924100 @default.
• W3094082904 hasConceptScore W3094082904C87355193 @default.
• W3094082904 hasConceptScore W3094082904C90924648 @default.
• W3094082904 hasConceptScore W3094082904C98274493 @default.
• W3094082904 hasIssue "3" @default.
• W3094082904 hasLocation W30940829041 @default.
• W3094082904 hasLocation W30940829042 @default.
• W3094082904 hasOpenAccess W3094082904 @default.
• W3094082904 hasPrimaryLocation W30940829041 @default.
• W3094082904 hasRelatedWork W1964002779 @default.
• W3094082904 hasRelatedWork W2003939908 @default.
• W3094082904 hasRelatedWork W2034115370 @default.
• W3094082904 hasRelatedWork W2152630501 @default.
• W3094082904 hasRelatedWork W2329628791 @default.
• W3094082904 hasRelatedWork W2407870820 @default.
• W3094082904 hasRelatedWork W2995422082 @default.
• W3094082904 hasRelatedWork W3100915479 @default.

• next